We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CTI BioPharma Corporation | NASDAQ:CTIC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.09 | 10.01 | 8.64 | 0 | 01:00:00 |
|
|
|
|
|
Delaware
|
|
001-12465
|
|
91-1533912
|
(State or other jurisdiction
of incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
•
|
Provide that each committee of the Board must have at least three members.
|
•
|
Provide that each director serving on a committee of the Board:
|
◦
|
meets the independence requirements of Listing Rule 5605 of the NASDAQ Stock Market’s Equity Rules;
|
◦
|
has not received, during the current calendar year or any of the three immediately preceding calendar years, remuneration, directly or indirectly, other than de minimis remuneration, as a result of service as, or compensation paid to an entity affiliated with the director that serves as: (A) an advisor, consultant, or legal counsel to the Corporation or to a member of the Corporation’s senior management; or (B) a significant customer or supplier of the Corporation;
|
◦
|
has no personal services contract(s) with the Corporation or any of its affiliates, or any of the Corporation’s executive officers;
|
◦
|
is not affiliated with a not-for-profit entity that receives significant contributions from the Corporation;
|
◦
|
has no interest in any investment that overlaps with an investment that the Corporation has (equity, debt or hybrid);
|
◦
|
during the current calendar year or any of the three immediately preceding calendar years, has not had any business relationship with the Corporation for which the Corporation has been required to make disclosure under Regulation S-K of the Securities Act of 1933, other than for service as a director or for which relationship no more than de minimis remuneration was received in any one such year; provided, however, that the need to disclose any relationship that existed prior to a director joining the Board shall not in and of itself render the director non-independent;
|
◦
|
is not employed by a public company at which an executive officer of the Corporation serves as a director;
|
◦
|
has not had any of the relationships described above, with any affiliate of the Corporation; and
|
◦
|
is not a member of the immediate family of any person described in subsections above.
|
Exhibit No.
|
|
Description
|
|
|
||||
|
|
|
|
|
|
|
CTI BIOPHARMA CORP.
|
||
Date: March 23, 2018
|
|
By:
|
|
/s/ David H. Kirske
|
|
|
|
|
David H. Kirske
|
|
|
|
|
Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit No.
|
|
Description
|
|||
|
1 Year CTI BioPharma Chart |
1 Month CTI BioPharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions